|
|
Post by compound26 on Oct 6, 2016 18:52:35 GMT -5
To begin, I want to thank all of you on this board for providing such good info. It was a great help. Not to be too sentimental, but it has been such a pleasure thus far being a part of this board and the common effort we are all a part of. I have no idea at this point whether my investment will ever pay off or go to zero. But I will honestly be able to say that I tried in my own small way to help the diabetic community hear about Afrezza and how it could improve their lives. So how did it go? My visit went very well but probably won't improve script counts in the near future.  I chose three documents to give to my GP. I did not want to hand him too much information. It included the following: 1. The article by Keith Campbell called Treating Diabetes In a Physiologic Manner 2. The 2016 ADA Abstract on the Earlier Onset and Shorter Duration of Technosphere Insulin 3. A clipped copy of the front page of afrezzajustbreath.com As expected of most GPs, he was running late and I knew I did not want to talk too much as he did not have a lot of time to see me. I went through my personal health issue as fast as possible and then asked him if he had researched Afrezza since I had mentioned it too him. As I expected, he had not (he is very busy). But he did say that their diabetic educator had just come back from a conference where Afrezza was mentioned and that he had now heard about Afrezza twice. With my visit, that would now be three times. He mentioned that he had been on an advisory board for Exhubera so he was familiar with the attempt at inhaled insulin. I gave him a quick run down of what documents I was giving him. I spoke about how fast Afrezza was in and gone and how current users of Afrezza were able to control both their highs and lows. I also mentioned that Afrezza seemed to work better if taken after eating began. This surprised him a little. I also mentioned that additional corrective doses could be taken if the meal was too big and because Afrezza was out so fast, the problem of insulin stacking was not an issue. There was only so much I could say in 5 minutes. But I talked fast. He thanked me giving him the information and asked how I came to know about this product. I told him I was an investor who had followed the product for nearly a decade. Although I am not diabetic, I said to him this is what I would want to take if I was ever diagnosed with diabetes. I have no idea how far this will go in terms of getting him on board. But I think he is intrigued that he has now heard about Afrezza three times in the last three months. Twice from me thank you very much. If he does try a patient on Afrezza and becomes convinced of its value, he does have influence in this area with other doctors. I will continue to spread the word and build on my new "information packet" to hand out. I will provide updates if I hear anything more. great effort! |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Oct 6, 2016 18:56:47 GMT -5
Time to email Mike the doc contact details for a Afrezza rep visit if the rep is visiting docs in that area - strike when the iron is hot
|
|
|
|
Post by mnholdem on Oct 6, 2016 19:08:33 GMT -5
Outstanding video, except the biker made me nervous. "Don't puff and drive." Wouldn't it be cool if he'd puffed with one hand while taking selfies with his phone in the other?  [Disclaimer: Don't take driving advice from lizards] I noticed that your avatar is not a lizard, but a chameleon. So you are saying, in effect, "don't take driving advice from others", while leaving the door open to the idea that your advice maybe can be trusted. That makes perfect sense, IMHO, because chameleons are so much smarter than lizards...
Me?
I worry more about the dangers of texting and flying:
|
|
|
|
Post by dreamboatcruise on Oct 6, 2016 19:21:13 GMT -5
Wouldn't it be cool if he'd puffed with one hand while taking selfies with his phone in the other? [Disclaimer: Don't take driving advice from lizards] I noticed that your avatar is not a lizard, but a chameleon. So you are saying, in effect, "don't take driving advice from others", while leaving the door open to the idea that your advice maybe can be trusted. That makes perfect sense, IMHO, because chameleons are so much smarter than lizards...
Me?
I worry more about the dangers of texting and flying:
All Chameleons are lizards, not all lizards are Chameleons. That Bridgestone is making me nervous. |
|
|
|
Post by wsb36 on Oct 6, 2016 23:19:46 GMT -5
centralcoastinvestor its dope what you did. Good work doing you part to get this cutting edge product into the hands of those who need it most. If you've ever read The Tipping Point you know the potential of centralcoastinvestor interaction with his doc. Ive been trying to concieve a way to fricken put Afrezza in the media spot light and all i got is this..we get a diabetic to crush a meal clearly high in sugar. He then takes his Afrezza via dreamboat then the JuJu song comes on and he does the JuJu dance. Onces hes done the dance *blur* and have Afrezza and Mannkind plastered. Audience wont be told that hes diabetic they have to catch on or ask questions and find out. The JuJu dance this is huge i feel its a fad we can ride. Plus the dreamboat in a video people will watch it 3 times like "wtf did he just hit?". Post it on insta. Get some hype. Someone big picks it up. BANG! 10 million people now know about Afrezza. I cant do it but its fun to visualize. Anyway I like your effort keep it up. Mannkind most likely thanks you.
|
|
|
|
Post by centralcoastinvestor on Jan 2, 2017 13:26:39 GMT -5
Hey slugworth008, I don't know how to copy a thread to your request about finding an old thread, so I just responded to this thread. There was some good advice offered in this thread regarding talking to others about Afrezza. So far, I have given my primary care doctor lots of documentation on Afrezza. He said he was interested. He is in charge of 13 different Dignity Health offices so I am excited about this contact. I have also given information to 4 different friends who either have diabetes or have a close friend struggling with it. As far as I am concerned, I'm just getting started.
|
|
|
|
Post by sportsrancho on Jan 2, 2017 16:48:06 GMT -5
I need help from the board:-)
I put #Afrezza on my Twitter posts. Well I just now tried clicking on one. All I see is MNKD longs arguing with risingskeptic ( the short ). I have blocked him because he lied to me, and told me there weren't any Endo's at the Rancho Medical presentation. We all need to block him so his crap doesn't show up everywhere! Or maybe there is another way around this? kc?
|
|
|
|
Post by kc on Jan 2, 2017 17:54:46 GMT -5
I need help from the board:-) I put #Afrezza on my Twitter posts. Well I just now tried clicking on one. All I see is MNKD longs arguing with risingskeptic ( the short ). I have blocked him because he lied to me, and told me there weren't any Endo's at the Rancho Medical presentation. We all need to block him so his crap doesn't show up everywhere! Or maybe there is another way around this? kc? I will look but I really don't know. As I had blocked him several weeks ago too |
|
|
|
Post by centralcoastinvestor on Jun 6, 2017 14:47:41 GMT -5
I just got back from my regular 6 month check up with my long time GP. I have very good news to report. After going through my own health status with him as quickly as possible, I asked him how his investigation into Afrezza was going. He said that after I gave him the information packet (thanks mannmade and so many others) at the last visit; he spoke soon after that with his office diabetic educator. And here's what he said (paraphrased). .... oh yeah, we think Afrezza is a good product, and my diabetic educater is prescribing it fairly often. I said really. Can I ask how many patients are on it now? He said 8 to 9. Yippeee. Now I don't know how much influence I had in this situation, but my saying something to him at each of the last three visits could not have hurt. Right? What blew me away was how matter of fact he was about prescribing it. It was like old news. That was awesome to hear. Prescribing Afrezza for his office is normal. He did say that insurance was still a pain. He is the lead administrator for approximately 80 doctors in this medical group. Let me repeat, prescribing Afrezza was a normal thing for his office now. Verrrrrry cool.
|
|
|
|
Post by sportsrancho on Jun 6, 2017 16:02:52 GMT -5
I just got back from my regular 6 month check up with my long time GP. I have very good news to report. After going through my own health status with him as quickly as possible, I asked him how his investigation into Afrezza was going. He said that after I gave him the information packet (thanks mannmade and so many others) at the last visit; he spoke soon after that with his office diabetic educator. And here's what he said (paraphrased). .... oh yeah, we think Afrezza is a good product, and my diabetic educater is prescribing it fairly often. I said really. Can I ask how many patients are on it now? He said 8 to 9. Yippeee. Now I don't know how much influence I had in this situation, but my saying something to him at each of the last three visits could not have hurt. Right? What blew me away was how matter of fact he was about prescribing it. It was like old news. That was awesome to hear. Prescribing Afrezza for his office is normal. He did say that insurance was still a pain. He is the lead administrator for approximately 80 doctors in this medical group. Let me repeat, prescribing Afrezza was a normal thing for his office now. Verrrrrry cool.[/quot ] It was all you IMO:-)) Great job central! He hadn't heard of it. And might not have heard of it yet! And even when they hear about it sometimes they dismiss it. Thank you for taking all that time and accomplishing so much! |
|
|
|
Post by lennymnkd on Jun 6, 2017 16:25:36 GMT -5
Need some help as well ! To who may be knowledgeable tech wise between onedrop and Dexcom ... are there any synergies in their technologies that might bring them together to from some type of business alliance .. like for instance onedrop s data advantage .. and dexcoms none invasive cgm technologies.. tia.
|
|
|
|
Post by promann on Jun 6, 2017 16:33:44 GMT -5
I just got back from my regular 6 month check up with my long time GP. I have very good news to report. After going through my own health status with him as quickly as possible, I asked him how his investigation into Afrezza was going. He said that after I gave him the information packet (thanks mannmade and so many others) at the last visit; he spoke soon after that with his office diabetic educator. And here's what he said (paraphrased). .... oh yeah, we think Afrezza is a good product, and my diabetic educater is prescribing it fairly often. I said really. Can I ask how many patients are on it now? He said 8 to 9. Yippeee. Now I don't know how much influence I had in this situation, but my saying something to him at each of the last three visits could not have hurt. Right? What blew me away was how matter of fact he was about prescribing it. It was like old news. That was awesome to hear. Prescribing Afrezza for his office is normal. He did say that insurance was still a pain. He is the lead administrator for approximately 80 doctors in this medical group. Let me repeat, prescribing Afrezza was a normal thing for his office now. Verrrrrry cool. That is great central, glad to hear stories like this but what I just can't figure out is why do we have such low script numbers when it seems like from what we are hearing that they should be skyrocketing? But I believe the point of script rise percentage will be huge in the next 1/4 with everything coming next month and all. We have exciting times coming.. Shorts will be gone by end of this year if they are smart  |
|
|
|
Post by centralcoastinvestor on Jun 6, 2017 16:36:10 GMT -5
Just as a quick FYI. I mentioned before that my doc is forward thinking. My doctor was using Google Glass during the appointment today to cut down on time spent taking notes. Certainly new to me. He's been doing this for a month.
|
|
|
|
Post by mnholdem on Jun 6, 2017 18:18:39 GMT -5
Perhaps soon you'll be introducing him to an Afrezza-OneDrop combination for his Type 2 and/or early diabetes patients. Great effort and I imagine that your educational fact-based approach and your enthusiasm helped win him over.
|
|
|
|
Post by InvesterSam on Jun 9, 2017 15:03:09 GMT -5
Description of Inhalable insulin seems pretty negative in wikipedia. Can this board help to edit the content with more positive vailidated info on Afrezza?
From Wikipedia, the free encyclopedia
Inhalable insulin is a powdered form of insulin, delivered with a nebulizer into the lungs where it is absorbed. A 2007 systematic review concluded that the inhaled hexameric insulin (Exubera) "appears to be as effective, but no better than injected short-acting insulin. The additional cost is so much more that it is unlikely to be cost-effective."[1]
Exubera, developed by Inhale Therapeutics (later named Nektar Therapeutics), became the first inhaled insulin product to be marketed in 2006 by Pfizer,[2] but poor sales led Pfizer to withdraw it in 2007.[3] Afrezza, a monomeric inhaled insulin developed by Mannkind, was approved by the FDA in 2014.[4]
History[edit]
Insulin was introduced by Banting and Best from the University of Toronto in 1921 as an injectable agent. German researchers first introduced the idea of inhalable insulin in 1924.[5] Years of failure followed until scientists realized they might be able to use new technologies to turn insulin into a concentrated powder with particles sized for inhalation.
In the 1980s Nektar Therapeutics developed technology to make insulin into small particles that they licensed to Pfizer; Alkermes developed a delivery device that they licensed to Eli Lilly and Company.[5]
Once concrete methods were developed, human tests began in the late 1990s.[5] In January 2006, the U.S. Food and Drug Administration (FDA) approved the use of Exubera, a form of inhalable insulin developed by Pfizer;[2] it was approved in the UK in August 2006 but reimbursed by the National Health Service only for people who had problems with needles.[6] However, in 2007, Pfizer announced that it would no longer manufacture or market Exubera. According to Chairman and CEO Jeffrey Kindler this was because Exubera "failed to gain acceptance among patients and physicians".[3]
At the time of Exubera's discontinuation, several other companies were pursuing inhaled insulin including Alkermes working with Eli Lilly and Company,[7] MannKind Corporation,[8][9] and Aradigm working with Novo Nordisk. By March 2008, all of these products had been discontinued except for MannKind's Afrezza product.[10]
On March 16, 2009 MannKind submitted an NDA for their inhalable insulin. In 2011 the FDA denied approval of Afrezza and because the design of the delivery device had changed, the FDA requested additional clinical trials to ensure that people would use it the same way as the earlier versions.[11] After conducting further studies, Mannkind submitted a new application, and in June, 2014, the FDA approved Afrezza for both Type I and Type II adult diabetics, with a label restriction for patients having asthma, active lung cancer or COPD.[4][12] In 2014 Mannkind and Sanofi agreed that Sanofi would take over manufacturing and marketing of Afrezza,[13] but Sanofi said it was dropping the effort in January 2016 due to poor sales of $7.5 million in 2015;[14] the companies formally terminated the agreement in November 2016.[15] At the time that Sanofi announced it was dropping the product Mannkind said it would continue alone,[14] and it had taken over manufacturing and relaunched the drug by July 2016.[15]
|
|
